| Dr Brian J Lenahan, DO | |
|
4003 S Route 59, Naperville, IL 60564-5802 | |
| (888) 693-6437 | |
| Not Available |
| Full Name | Dr Brian J Lenahan |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 21 Years |
| Location | 4003 S Route 59, Naperville, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053462788 | NPI | - | NPPES |
| P00412092 | Other | RAILROAD MEDICARE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 036114526 (Illinois) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dupage Medical Group Ltd | 5496667941 | 1209 |
News Archive
Today AIDS Healthcare Foundation (AHF) commented on an editorial published in the September 2011 issue of The Lancet Infectious Diseases that raises concerns about the use of the HIV treatment drug Truvada, manufactured by Gilead Sciences Inc., as an HIV prevention pill or pre-exposure prophylaxis (PrEP), agreeing with the publication's public health concerns.
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.
A study by Dartmouth and Australian researchers provides the first empirical evidence using data from a variety of countries that foreign aid can greatly improve foreign public opinion of donor countries.
Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.
Research shows that in cases of inflammatory joint disease, the earlier you catch the disease and suppress the immune system, the less likely a patient is to develop damaging and ongoing, chronic inflammation.
› Verified 3 days ago
| Entity Name | Dupage Medical Group Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801833983 PECOS PAC ID: 5496667941 Enrollment ID: O20031110000535 |
News Archive
Today AIDS Healthcare Foundation (AHF) commented on an editorial published in the September 2011 issue of The Lancet Infectious Diseases that raises concerns about the use of the HIV treatment drug Truvada, manufactured by Gilead Sciences Inc., as an HIV prevention pill or pre-exposure prophylaxis (PrEP), agreeing with the publication's public health concerns.
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.
A study by Dartmouth and Australian researchers provides the first empirical evidence using data from a variety of countries that foreign aid can greatly improve foreign public opinion of donor countries.
Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.
Research shows that in cases of inflammatory joint disease, the earlier you catch the disease and suppress the immune system, the less likely a patient is to develop damaging and ongoing, chronic inflammation.
› Verified 3 days ago
| Entity Name | Central Dupage Hospital Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003864810 PECOS PAC ID: 0941108666 Enrollment ID: O20031231000723 |
News Archive
Today AIDS Healthcare Foundation (AHF) commented on an editorial published in the September 2011 issue of The Lancet Infectious Diseases that raises concerns about the use of the HIV treatment drug Truvada, manufactured by Gilead Sciences Inc., as an HIV prevention pill or pre-exposure prophylaxis (PrEP), agreeing with the publication's public health concerns.
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.
A study by Dartmouth and Australian researchers provides the first empirical evidence using data from a variety of countries that foreign aid can greatly improve foreign public opinion of donor countries.
Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.
Research shows that in cases of inflammatory joint disease, the earlier you catch the disease and suppress the immune system, the less likely a patient is to develop damaging and ongoing, chronic inflammation.
› Verified 3 days ago
| Entity Name | Central Dupage Physician Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1033149844 PECOS PAC ID: 5890696231 Enrollment ID: O20040303000601 |
News Archive
Today AIDS Healthcare Foundation (AHF) commented on an editorial published in the September 2011 issue of The Lancet Infectious Diseases that raises concerns about the use of the HIV treatment drug Truvada, manufactured by Gilead Sciences Inc., as an HIV prevention pill or pre-exposure prophylaxis (PrEP), agreeing with the publication's public health concerns.
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.
A study by Dartmouth and Australian researchers provides the first empirical evidence using data from a variety of countries that foreign aid can greatly improve foreign public opinion of donor countries.
Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.
Research shows that in cases of inflammatory joint disease, the earlier you catch the disease and suppress the immune system, the less likely a patient is to develop damaging and ongoing, chronic inflammation.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Brian J Lenahan, DO Po Box 713260, Chicago, IL 60677-1260 Ph: (630) 469-2000 | Dr Brian J Lenahan, DO 4003 S Route 59, Naperville, IL 60564-5802 Ph: (888) 693-6437 |
News Archive
Today AIDS Healthcare Foundation (AHF) commented on an editorial published in the September 2011 issue of The Lancet Infectious Diseases that raises concerns about the use of the HIV treatment drug Truvada, manufactured by Gilead Sciences Inc., as an HIV prevention pill or pre-exposure prophylaxis (PrEP), agreeing with the publication's public health concerns.
Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced the re-launch of FOCUS (http://www.vyvanseFOCUS.com), a free, online patient support program for adults taking once-daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), and the only online, branded personalized patient support program providing tips and tools for adults diagnosed with ADHD taking a prescription medication.
A study by Dartmouth and Australian researchers provides the first empirical evidence using data from a variety of countries that foreign aid can greatly improve foreign public opinion of donor countries.
Millennium: The Takeda Oncology Company today announced data from clinical trials of four investigational compounds in solid tumors presented at the Annual Meeting of the American Society of Clinical Oncology, held in Chicago, Illinois, June 4-8, 2010. These data include an oral presentation on MLN8237, the Company's selective Aurora A kinase inhibitor.
Research shows that in cases of inflammatory joint disease, the earlier you catch the disease and suppress the immune system, the less likely a patient is to develop damaging and ongoing, chronic inflammation.
› Verified 3 days ago
Cortney Cole, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 801 S Washington St, Naperville, IL 60540 Phone: 630-527-3000 | |
Michael E Peters, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3360 Lacrosse Ln, Suite 106, Naperville, IL 60564 Phone: 630-696-4404 Fax: 630-696-4405 | |
Dr. Francis Antony, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1220 Hobson Road, Ste 104, Naperville, IL 60540 Phone: 630-416-1950 Fax: 630-646-5610 | |
Dr. Molly M D'costa, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2710 111th Street, Naperville, IL 60565 Phone: 630-355-9531 Fax: 630-355-9532 | |
Dr. Terry May, D.O. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1891 Bayscott Circle, Ste 109, Naperville, IL 60540 Phone: 630-527-6400 | |
Dr. Barbara Jean Opalka, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2940 Rollingridge Rd, Suite 101, Naperville, IL 60564 Phone: 630-637-8630 Fax: 630-637-8640 |